贝达喹啉、普托马尼和利奈唑胺(BPaL)为基础方案在非试验环境下治疗利福平耐药结核的有效性和安全性——白俄罗斯和乌兹别克斯坦的前瞻性队列研究
该前瞻性队列研究在白俄罗斯和乌兹别克斯坦纳入677例耐多药/利福平耐药结核(MDR/RR-TB)及准广泛耐药结核(pre-XDR-TB)患者,评估以BPaL为基础方案的有效性和安全性。MDR/RR-TB患者接受BPaL联合莫西沙星治疗的成功率为95.3%(427/448),pre-XDR-TB患者接受BPaL联合氯法齐明治疗的成功率为90.4%(207/229)。10.2%(69/677)发生严重不良事件,包括24例死亡(3.5%),其中11例发生于治疗期间;83.3%(20/24)的死亡与结核或结核治疗无关。完成12个月随访的成功治疗患者中复发率为0.5%(2/383)。作者认为这些方案在非试验环境下安全且高效,应考虑全球推广,并需进一步研究在其他关键人群中的表现。
要点
- MDR/RR-TB患者接受BPaL联合莫西沙星治疗成功率为95.3%(427/448)。
- pre-XDR-TB患者接受BPaL联合氯法齐明治疗成功率为90.4%(207/229)。
- 严重不良事件发生率10.2%(69/677),死亡3.5%(24/677),其中83.3%(20/24)与结核或结核治疗无关。
核心结论
- 以BPaL为基础方案在非试验环境下治疗MDR/RR-TB和pre-XDR-TB安全且高效。
- 作者认为这些方案应考虑全球广泛实施,并需进一步研究评估其在其他关键人群中的表现。
研究设计与样本
- 前瞻性队列研究,纳入白俄罗斯和乌兹别克斯坦 microbiologically confirmed MDR/RR-TB 及 pre-XDR-TB 患者,于2022年2月至2023年6月启动以BPaL为基础方案治疗。
- 所有临床诊疗和研究程序由治疗医生实施;治疗完成后在6个月和12个月随访,包括收集痰标本以确认复发。
- 主要目标为评估以BPaL为基础方案的有效性(治愈或完成治疗)和安全性(严重不良事件的发生)。
主要发现
- 共677例患者启动以BPaL为基础方案治疗。
- MDR/RR-TB患者接受BPaL联合莫西沙星治疗的成功率为95.3%(427/448)。
- pre-XDR-TB患者接受BPaL联合氯法齐明治疗的成功率为90.4%(207/229)。
- 10.2%(69/677)发生严重不良事件,包括24例死亡(3.5%),其中11例发生于治疗期间。
- 83.3%(20/24)的死亡与结核或结核治疗无关;完成12个月随访的成功治疗患者中复发率为0.5%(2/383)。
临床怎么用
- 作者认为以BPaL为基础方案在非试验环境下治疗MDR/RR-TB和pre-XDR-TB安全且高效,应考虑全球广泛实施。
- 作者建议进一步研究评估这些方案在其他关键人群中的表现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Week all-oral bedaquiline, pretomanid, and linezolid (BPaL)-based regimens have demonstrated higher rates of treatment success and have been recommended by the World Health Organization. Operational research is urgently required to evaluate these regimens in non-trial settings. METHODS: This was a prospective cohort study of patients with microbiologically confirmed MDR/RR-TB and pre-extensively drug-resistant TB (pre-XDR-TB) initiated on BPaL-based regimens in Belarus and Uzbekistan (February 2022-June 2023). All clinical care and research procedures were delivered by treating physicians. After treatment completion, patients were followed up at 6 and 12 months, including collecting sputum to ascertain recurrence. The primary objective was to estimate the effectiveness (cured or treatment completed) and safety (the occurrence of serious adverse events) of BPaL-based regimens. RESULTS: A total of 677 patients initiated treatment with BPaL-based regimens during the study. We documented successful treatment outcomes in 95.3% (427/448) of patients with MDR/RR-TB treated with BPaL plus moxifloxacin and 90.4% (207/229) of patients with pre-XDR-TB treated with BPaL plus clofazimine. 10.2% (69/677) experienced serious adverse events including 24 deaths (3.5%), 11 of which occurred during treatment. 83.3% (20/24) of deaths were not related to TB or TB treatment. Of patients who were successfully treated and completed 12-month follow-up, 0.5% (2/383) had recurrence. CONCLUSIONS: BPaL-based regimens for MDR/RR-TB and pre-XDR-TB are safe and highly effective in non-trial settings. These regimens should be considered for widespread implementation globally, and further research is needed to evaluate their performance in other key populations.
引用
- Sinha A, Klebe R, Rekart ML, et al. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan. Clin Infect Dis. 2025. PMID: 39964841. doi:10.1093/cid/ciaf035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。